Department of Hepatobiliary Surgery, Eastern Hepatobiliary Surgery Hospital, Naval Medical University (Second Military Medical University).
Eastern Hepatobiliary Clinical Research Institute, Third Affiliated Hospital of Naval Medical University.
Int J Surg. 2023 Apr 1;109(4):841-849. doi: 10.1097/JS9.0000000000000325.
The presence of microvascular invasion (MVI) is a significant malignant pathological feature related to recurrence and survival after liver resection for hepatocellular carcinoma (HCC). This study aimed to investigate the relationship between the severity in the grading of MVI and long-term oncological outcomes in patients with early-stage HCC.
A retrospective study was conducted on a prospectively maintained multicenter database on patients who underwent curative resection for Barcelona Clinic Liver Cancer stage 0/A HCC between 2017 and 2020. Patients were classified into three groups according to the severity in the grading of MVI: M0 (no MVI), M1 (1-5 sites of MVI occurring ≤1 cm away from the tumor), and M2 (>5 sites occurring ≤1 cm and/or any site occurring >1 cm away from the tumor). Recurrence-free survival (RFS) and overall survival (OS) were compared among the groups.
Of 388 patients, M0, M1, and M2 of the MVI gradings were present in 223 (57.5%), 118 (30.4%), and 47 (12.1%) patients, respectively. The median OS and RFS in patients with M0, M1, and M2 were 61.1, 52.7, and 27.4 months; and 43.0, 29.1, and 13.1 months (both P <0.001), respectively. Multivariable analyses identified both M1 and M2 to be independent risk factors for OS [hazard ratio (HR): 1.682, P =0.003; and HR: 3.570, P <0.001] and RFS (HR: 1.550, P =0.037; and HR: 2.256, P <0.001).
The severity in the grading of MVI was independently associated with recurrence and survival after HCC resection. Patients with the presence of MVI, especially those with a more severe MVI grading (M2), require more stringent recurrence surveillance and/or active adjuvant therapy against recurrence.
微血管侵犯(MVI)的存在是与肝癌(HCC)切除术后复发和生存相关的重要恶性病理特征。本研究旨在探讨早期 HCC 患者中 MVI 分级严重程度与长期肿瘤学结果的关系。
对 2017 年至 2020 年间接受巴塞罗那临床肝癌(BCLC)0/A 期 HCC 根治性切除术的患者进行前瞻性多中心数据库的回顾性研究。根据 MVI 分级的严重程度,患者分为三组:M0(无 MVI)、M1(1-5 个 MVI 部位发生在距肿瘤≤1cm 处)和 M2(>5 个部位发生在距肿瘤≤1cm 处和/或任何部位发生在距肿瘤>1cm 处)。比较各组之间的无复发生存率(RFS)和总生存率(OS)。
在 388 例患者中,M0、M1 和 M2 的 MVI 分级分别为 223 例(57.5%)、118 例(30.4%)和 47 例(12.1%)。M0、M1 和 M2 患者的中位 OS 和 RFS 分别为 61.1、52.7 和 27.4 个月和 43.0、29.1 和 13.1 个月(均 P<0.001)。多变量分析发现 M1 和 M2 均是 OS(危险比[HR]:1.682,P=0.003;和 HR:3.570,P<0.001)和 RFS(HR:1.550,P=0.037;和 HR:2.256,P<0.001)的独立危险因素。
MVI 分级严重程度与 HCC 切除术后的复发和生存独立相关。存在 MVI 的患者,特别是 MVI 分级更严重(M2)的患者,需要更严格的复发监测和/或积极的辅助治疗以预防复发。